PATERGRUS BVBA

Their core work

PATERGRUS BVBA, operating as BiotechSubsidy, is a Belgian SME specializing in subsidy consulting and project management for biotech and pharmaceutical companies pursuing EU-funded clinical development. They help biotech firms navigate funding for advanced therapies — from rare disease treatments like cystic fibrosis drugs to mRNA-based cancer vaccines. Their consistent presence across health-focused H2020 projects suggests they provide regulatory, financial, or administrative support to move therapies from preclinical stages toward clinical trials.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2017) split between rare disease drug development (cystic fibrosis oligonucleotide therapy) and industrial biotechnology (biobased economy). From 2018 onward, they concentrated entirely on advanced clinical-stage health projects — personalised CF treatments using organoids and mRNA cancer vaccines targeting HPV-related tumours. The trajectory shows a clear narrowing from general biotech support toward late-stage clinical development in high-impact therapeutic areas.

Moving toward mRNA therapeutics and personalised medicine — expect future involvement in oncology immunotherapy and precision treatment platforms.

How they like to work

Always a participant, never a coordinator — they join consortia rather than lead them, consistent with a consulting or support role. With 33 unique partners across 11 countries from just 4 projects, they operate in large, multi-national consortia typical of clinical trial networks. This makes them an accessible partner: experienced in complex consortium dynamics without competing for leadership positions.

Connected to 33 partners across 11 countries through four projects, giving them a broad European network despite their small size. Their partnerships span academic medical centres, pharma companies, and patient organisations involved in clinical research.

What sets them apart

Their brand name says it all — BiotechSubsidy is one of the few SMEs explicitly focused on helping biotech companies secure and manage EU funding for clinical development. Unlike research institutes or pharma companies in the same projects, they bring grant expertise rather than lab capacity. For a biotech startup or mid-size pharma needing to navigate Horizon Europe funding for a clinical trial, this is a purpose-built partner.

Highlights from their portfolio

• HIT-CF
  Large-scale personalised medicine project using intestinal organoids to treat ultra-rare cystic fibrosis mutations — running through 2025 with significant funding (EUR 302K to PATERGRUS alone).
• TIGER
  Proof-of-principle for a therapeutic mRNA cancer vaccine (TriMix platform) targeting HPV-related cancers — positions them at the frontier of mRNA therapeutics beyond COVID applications.
• PRO-CF-MED
  Their largest single grant (EUR 330K) for a first-in-humans clinical trial of an RNA-targeting oligonucleotide for cystic fibrosis — demonstrates involvement from early clinical stages.